{"title":"Second Phase 3 trial shows benefit of xanomeline-trospium in schizophrenia","authors":"","doi":"10.1002/pu.31190","DOIUrl":null,"url":null,"abstract":"<p>A 5-week trial has found that the combination of the muscarinic receptor agonist xanomeline and the peripheral muscarinic antagonist trospium significantly reduced symptoms of schizophrenia in adults. The xanomeline-trospium combination was well-tolerated, with no significant difference from placebo in extrapyramidal symptoms or weight gain.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31190","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A 5-week trial has found that the combination of the muscarinic receptor agonist xanomeline and the peripheral muscarinic antagonist trospium significantly reduced symptoms of schizophrenia in adults. The xanomeline-trospium combination was well-tolerated, with no significant difference from placebo in extrapyramidal symptoms or weight gain.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
